BGC Group trades at 5.9x forward earnings. Every exchange peer — CME, Tradeweb, Nasdaq, CBOE, MarketAxess — trades at 25-30x. Either the market is right that BGC is still just an interdealer broker, or there's a 4-5x gap between what BGC IS and what the market THINKS it is.

The 10-K confirms it's the latter.

The Numbers

FMX UST, BGC's electronic Treasury platform, now commands 39% of the central limit order book market for U.S. Treasuries. That's up from 37% in Q3, 30% a year ago, and roughly 19% two years ago. Market share has increased in 12 of the last 13 quarters. This isn't a good quarter. It's a compounding network effect that has doubled share in twelve months. CME's BrokerTec is bleeding.

FMX Futures, the exchange that matters for reclassification, hit 1% market share in January 2026 for the first time. Q4 2025 saw ADV increase 82% and open interest increase 97% — sequentially, not year-over-year. SOFR futures launched September 2024. Treasury futures (2-year and 5-year) launched May 2025. Ten of the world's largest financial institutions — Goldman, JPM, Citi, BofA, Barclays, Morgan Stanley, Citadel Securities, Wells Fargo, Jump, Tower Research — committed $172 million for a 25.75% equity stake, with an additional 10.3% tied to volume targets.

Two analysts cover this stock. Both have targets above $14. The market isn't paying attention.

CME Confirms the Threat (In Legal Filings, Not on Calls)

Here's where it gets interesting. CME's 10-K, filed February 26, names "newly launched FMX Futures Exchange" as a competitive threat — listed alongside ICE, Cboe, Euronext, and HKEX. That's a legally required disclosure. CME's lawyers don't name 1% market share competitors for fun.

Meanwhile, CME's Q4 2025 earnings call — a voluntary, managed narrative — mentions FMX zero times. Not once. Not in prepared remarks, not in Q&A. CEO Duffy spent the call on record futures volumes, event contracts, crypto, and cross-margining. BrokerTec? Treasury CLOB dynamics? Silence.

This is textbook incumbent behavior. You acknowledge threats in your 10-K because the lawyers make you. You ignore them on earnings calls because acknowledging a challenger legitimizes it. When analysts start asking CME about FMX — that's the rerate catalyst.

CME also built BrokerTec Chicago in October 2025: a second CLOB for cash Treasuries, co-located with futures in Aurora. You don't build a second CLOB if you're winning on the first one.

The Moat Question: Why Eurex Failed and FMX Might Not

The smart bear case isn't governance or leverage. It's cross-margining.

CME offers $80 billion per day in margin savings across six asset classes. A trader keeping futures at CME gets capital offsets against other CME products via FICC. Moving to FMX means losing those offsets. This is what killed Eurex's Treasury futures challenge in 2004-2005 — they offered fee discounts but couldn't match the capital savings of CME's cross-margining.

Case closed? No.

FMX clears through LCH SwapClear. LCH holds $225 billion in interest rate swap margin — six times CME's $37 billion futures margin pool. FMX's cross-margining proposition isn't futures-vs-futures (CME's game). It's futures-vs-swaps. The 10 bank partners hold trillions in interest rate swaps at LCH. Cross-margining their FMX futures against those swap positions potentially saves MORE capital than keeping everything at CME.

Eurex had one incentive: lower fees. FMX has three: lower fees, equity ownership (up to 36% of FMX if volume targets are met), and a larger cross-margin pool via LCH. The first Marex portfolio-margin trade on FMX went live in October 2025. Early, but the infrastructure exists.

This is the detail that shifts the analysis from "interesting misclassification" to "the moat has a crack and the water is already flowing through."

The Governance Problem

Howard Lutnick built BGC over 30 years. He was confirmed as Commerce Secretary on February 18, 2025, divested all holdings by October, and handed control to his son Brandon. Brandon Lutnick is approximately 30 years old, controls 72% of BGC's voting power through 10-vote Class B shares, and has no public track record running a company of this complexity. Three co-CEOs were appointed simultaneously — a structure that signals no clear successor existed.

It gets worse. Rep. Raskin sent a letter on February 27 demanding documents from both Lutnicks regarding allegations that Cantor Fitzgerald bought tariff refund rights at 20-30 cents on the dollar before SCOTUS struck down Trump's tariffs — while Howard was publicly championing those same tariffs as Commerce Secretary. Cantor's official denial is specific: "never executed any transactions or taken any position on tariffs refund claims." They did admit salespeople "explored brokering" in July 2025. Deadline for documents: March 9.

This probably goes nowhere. Minority party investigations have limited subpoena power, the denial is legally precise, and tariff refund brokering isn't illegal per se. But the headlines are poison for institutional discovery. No PM at a serious fund is initiating a position in a stock where the controlling shareholder's family is under Congressional investigation. This could delay the rerate by 6-12 months.

Factor Decomposition

Factor regression shows 75.6% idiosyncratic variance. Company-specific factors drive returns, not market or momentum. Beta is 0.77. Backward alpha is -3.8% annually — the stock has underperformed after removing market factors, which is exactly what "not yet rerated" looks like.

Seven independent factors:

The edge is in factors 1 and 2: tracking FMX platform metrics that only 2 analysts follow, cross-referencing CME's filings for confirmation, and understanding the LCH cross-margin advantage that changes the Eurex precedent.

The Math

Eighteen-month scenarios:

Bull (25%): FMX Futures hits 5%+, analyst coverage expands, market rerates to 18-20x. Target: $28.

Base (50%): FMX Futures grows to 3%, Fenics revenue mix becomes visible, partial rerate to 10-12x. Target: $16.

Bear (25%): FMX Futures stalls, governance issues persist, stays at 5-7x. Target: $8.

Expected value: $17.00, roughly +82% from $9.34. Annualized forward alpha after removing market factors: approximately 38%, implying a Sharpe ratio of 1.3 on 29% idiosyncratic volatility.

The asymmetry is the point. In the bear case, you lose 15% from an already-cheap 5.9x multiple. In the base case, you roughly double. In the bull case, you triple. The downside is modest because the stock is already priced as if FMX doesn't exist.

What to Watch

March 9: Raskin document deadline. If nothing material surfaces, governance overhang starts to fade.

Q1 2026 volumes: Does FMX Futures sustain the January 1% pace through February and March? Sequential momentum is the leading indicator.

LCH adoption: How many of the 10 bank partners are actually running portfolio-margin on FMX? Marex was first in October 2025. The second and third names matter more than the first.

Analyst initiations: Only 2 analysts cover BGC. A third initiation — particularly from a major bank — would be the discovery catalyst. Both existing targets ($14-15) are 50%+ above current.

CME earnings calls: The day an analyst asks Terry Duffy about FMX on a quarterly call is the day the market starts repricing BGC.